HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)

The summary for the HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21): Despite progress in HIV/AIDS treatment and prevention and reductions in HIV/morbidity and mortality, HIV/AIDS health disparities remain a challenge that must be addressed. This FOA encourages research to identify the role(s) that drug abuse plays in fueling the epidemic in vulnerable groups (racial/ethnic minorities, men who have sex with men (MSM), youth) in the United States and to develop effective interventions to prevent new infections and to improve the health and well-being of those living with HIV/AIDS. This FOA will support studies in vulnerable populations to: 1) understand the contribution of drug abuse (both injection and non-injection) to the acquisition and/or transmission of HIV; 2) study disease progression and disease outcomes; 3) develop and/or improve prevention and treatment interventions, particularly comprehensive, integrated interventions; 4) improve the availability, delivery and quality of evidence-based prevention and treatment services across a variety of settings; and 5) address organizational, structural, and/or community level factors including social, drug-using, and sexual networks associated with health disparities.
Federal Grant Title: HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-12-280
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: Jan 07, 2016
Original Application Deadline: Jan 07, 2016
Posted Date: September 10th, 2012
Creation Date: Sep 10, 2012
Archive Date: Feb 07, 2016
Total Program Funding:
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Tri...
Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clin...
Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Cl...
Leveraging Big Data Science to Elucidate the Neural Mechanisms of Addiction and Substance ...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K0...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R...
Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinica...
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com